Excerpt
Despite the growing role of next-generation sequencing (NGS) in guiding personalized cancer therapies, real-world data reveal that only 30% to 40% of patients with advanced cancers undergo this critical testing. Alarmingly, a significant number receive results too lateโoften within the final three months of lifeโlimiting access to targeted treatments that could improve or extend survival. These findings highlight an urgent need to integrate NGS testing earlier in the cancer care continuum.